Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer HealthCare and Compugen agree cancer alliance

Bayer HealthCare and Compugen agree cancer alliance

6th August 2013

Bayer HealthCare has announced plans to ally with Compugen on the development of new treatments for cancer.

A collaboration and license agreement has been signed for the research, development and commercialisation of antibody-based therapeutics for cancer immunotherapy against two novel Compugen-discovered immune checkpoint regulators.

The deal will see the companies jointly pursuing a preclinical research programme, with Bayer subsequently gaining full control over further development and worldwide commercialisation rights for potential therapeutics.

Therapies of this kind hold the potential to combat the immunosuppressive function of many cancers, thus reactivating the patient's anti-tumour immune response.

Professor Andreas Busch, member of the Bayer HealthCare executive committee and head of global drug discovery, said: "Bayer is committed to translating the science of cancer research into effective therapies helping people affected by cancer live longer and improve their quality of life."

This comes after Bayer published its second-quarter financial results earlier this month, revealing that its healthcare division experienced year-on-year growth of 3.8 percent during the period.ADNFCR-8000103-ID-801621288-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.